Trehalose dimycolate elicits eosinophilic skin hypersensitivity in mycobacteria-infected guinea pigs.
Delayed-type hypersensitivity represents high levels of protein Ag-specific adaptive immunity induced by mycobacterial infection, and can be monitored in the Ag-challenged skin. Besides protein Ags, recent evidence has suggested that a substantial immunity directed against glycolipid Ags is also elicited in response to mycobacterial infection, but skin hypersensitivity to this class of Ags has not been fully assessed. To address this issue directly, glycolipid-specific skin reactions were evaluated in guinea pigs infected with Mycobacterium avium complex (MAC). Significant skin induration was observed in MAC-infected, but not mock-infected, guinea pigs, following intradermal administration of a mixture of MAC-derived glycolipids. Surprisingly, this glycolipid-specific skin response involved up-regulated expression of IL-5 mRNA in situ and marked local infiltration of eosinophils. Challenge experiments with individual glycolipid components detected an outstanding capability for trehalose dimycolate (TDM), but not a structurally related glycolipid, glucose monomycolate, to elicit the skin response. T lymphocytes derived from the spleen of MAC-infected, but not uninfected, guinea pigs specifically responded to TDM in vitro by up-regulating IL-5 transcription, and this response was not blocked by Abs that reacted to the known guinea pig group 1 CD1 proteins. Finally, the eosinophilic skin hypersensitivity to TDM was also elicited in guinea pigs vaccinated with bacillus Calmette-Guerin, which contrasted sharply with the classical delayed-type hypersensitivity response to the purified protein derivative. Therefore, the TDM-elicited eosinophilic response defines a new form of hypersensitivity in mycobacterial infection, which may account for local infiltration of eosinophils often observed at the site of infection.
Otsuka
Atsushi
A
Laboratory of Cell Regulation, Institute for Virus Research, Kyoto University, Kyoto, Japan.
Matsunaga
Isamu
I
Komori
Takaya
T
Tomita
Kadusa
K
Toda
Yoshinobu
Y
Manabe
Toshiaki
T
Miyachi
Yoshiki
Y
Sugita
Masahiko
M
D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000818:Animals; D002465:Cell Movement / Q000276:immunology; D003311:Cord Factors / Q000008:administration & dosage* / Q000276:immunology*; D004804:Eosinophils / Q000276:immunology* / Q000473:pathology / Q000648:ultrastructure; D005260:Female; D006168:Guinea Pigs; D006968:Hypersensitivity, Delayed / Q000276:immunology* / Q000382:microbiology / Q000473:pathology; D015848:Interleukin-5 / Q000096:biosynthesis; D007428:Intradermal Tests; D009162:Mycobacterium avium / Q000276:immunology* / Q000378:metabolism; D009163:Mycobacterium bovis / Q000276:immunology* / Q000378:metabolism; D013154:Spleen / Q000276:immunology / Q000382:microbiology / Q000473:pathology; D014376:Tuberculosis / Q000276:immunology / Q000382:microbiology / Q000473:pathology
D000276:Adjuvants, Immunologic; D003311:Cord Factors; D015848:Interleukin-5